BioCentury | Oct 17, 2020
Translation in Brief

SARS-CoV-2 infects brain choroid plexus, compromises CSF-blood barrier; plus Passage’s GM1 gangliosidosis gene therapy, a new COVID-19 reporter and more

SARS-CoV-2 infects brain choroid plexusA team from Medical Research Council Laboratory of Molecular Biology (MRC LMB) have found that SARS-CoV-2 infects the CSF-producing brain choroid plexus — but not...
BioCentury | Oct 14, 2020
Product Development

A third leading COVID program enters holding pattern as NIH pauses testing of Lilly’s mAb

The launch of NIH’s Phase II ACTIV-5 Big Effect Trial study of anti-inflammatory mAbs Skyrizi from AbbVie and Boehringer and lenzilumab from Humanigen to treat hospitalized COVID-19 patients has coincided...
BioCentury | Oct 3, 2020
Product Development

Departing Alnylam, Greene has messages for industry from company building to product pricing

As Barry Greene departs Alnylam, he believes the modality he nurtured from plan to reality has the potential to sit alongside mAbs and small molecules as an agent of choice. Greene announced in August...
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

Liquid biopsy company Thrive Earlier Detection Corp. hired Sam Asgarian as CMO, Frank Diehl as EVP of product solutions and Dina Ciarimboli as chief legal officer. Before joining Thrive, Asgarian was VP of the transformation health product organization at...
BioCentury | Sep 30, 2020
Deals

As China’s CStone preps for launches, Pfizer buys equity stake and local rights to PD-L1 program

A deal giving Pfizer local rights to CStone’s PD-L1 inhibitor will add at least $200 million to the Suzhou-based biotech’s balance sheet as it prepares for a series of drug approvals, while taking advantage of...
BioCentury | Sep 29, 2020
Management Tracks

Garijo picked to succeed Oschmann at Merck KGaA; plus BioShin, Abeona, Rubius, Nimbus, Vizgen

Stefan Oschmann will hand the titles of executive board chair and CEO of Merck KGaA (Xetra:MRK) to Belén Garijo on May 1, 2021. Garijo is the German company’s vice chair and deputy CEO, as well...
BioCentury | Sep 25, 2020
Management Tracks

Lopes-Fernandes to lead BD for Ipsen; plus

Philippe Lopes-Fernandes will join Ipsen Group (Euronext:IPN; Pink:IPSEY) in its Cambridge, Mass., office as EVP and CBO on Oct. 1. Before joining Ipsen, Philippe was SVP, global head of BD and alliance management at Merck KGaA (Xetra:MRK)....
BioCentury | Sep 16, 2020
Product Development

Pace of Monjuvi’s growth may dictate how quickly MorphoSys can rebuild its pipeline

MorphoSys’ first marketed therapeutic, Monjuvi, has the makings of a blockbuster, but the company and partner Incyte will need to execute on the drug’s launch and planned label expansions to generate the...
BioCentury | Sep 9, 2020
Product Development

Roche’s Anderson wants industry to keep its foot on the gas for infectious disease, post-pandemic: a BioCentury audio interview

There will be no turning back to business as usual for drug developers and regulators after COVID-19, according to Bill Anderson, CEO of Roche Pharmaceuticals. But while he’s optimistic about speeding up timelines and changing...
BioCentury | Sep 5, 2020
Deals

Deal with AbbVie, PIPE triples I-Mab’s cash, positions biotech to be among China’s CD47 leaders

Immuno-oncology company I-Mab nearly tripled its cash position on Friday, adding more than $600 million to its coffers through a CD47 licensing deal with AbbVie and a PIPE financing led by Hillhouse Capital. The deal...
Items per page:
1 - 10 of 1172